Effect of lithium chloride and antineoplastic drugs on survival and cell cycle of androgen-dependent prostate cancer LNCap cells

Indian Journal of Pharmacology

Volumn 44, Issue 6, 2012, Pages 714-721

  Azimian Zavareh, Vajihe ^a,b   Hossein, Ghamartaj ^a   Janzamin, Ehsan ^b  

^a UNIVERSITY OF TEHRAN   (Iran)

^b ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

Author keywords

Antineoplastic drugs; combination therapy; glycogen synthase kinase 3 ; lithium chloride; prostate cancer

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANDROGEN; ANTINEOPLASTIC AGENT; DOXORUBICIN; ETOPOSIDE; LITHIUM CHLORIDE; VINCRISTINE;

APOPTOSIS; ARTICLE; ASSAY; CELL CYCLE; CELL STRAIN LNCAP; CELL SURVIVAL; CYTOTOXICITY; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; M PHASE CELL CYCLE CHECKPOINT; PROSTATE CANCER; S PHASE CELL CYCLE CHECKPOINT;

ANDROGENS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOXORUBICIN; DRUG THERAPY, COMBINATION; ETOPOSIDE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LITHIUM CHLORIDE; MALE; PROSTATIC NEOPLASMS; VINBLASTINE;

EID: 84870013178     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.103265     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC, Mizokami A, et al. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem 1999;274:8316-21.
3. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A 1999;96:5458-63.
4. Culig Z, Hobisch A, Bartsch G, Klocker H. Androgen receptor-an update of mechanisms of action in prostate cancer. Urol Res 2000;28:211-9.
5. Sivanandam A, Murthy S, Kim SH, Barrack ER, Veer Reddy GP. Role of androgen receptor in prostate cancer cell cycle regulation: Interaction with cell cycle regulatory proteins and enzymes of DNA synthesis. Curr Protein Pept Sci 2010;11:451-8.
6. Kim L, Kimmel AR. GSK3, a master switch regulating cell-fate specification and tumorigenesis. Curr Opin Genet Dev 2000;10:508-14.
7. Liao X, Thrasher JB, Holzbeierlein J, Stanley S, Li B. Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 2004;145:2941-9.
8. Mazor M, Kawano Y, Zhu H, Waxman J, Kypta RM. Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene 2004;23:7882-92.
9. Wang L, Lin HK, Hu YC, Xie S, Yang L, Chang C. Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells. J Biol Chem 2004;279:32444-52.
10. Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, et al. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 2004;279:19191-200.
11. Sun A, Shanmugam I, Song J, Terranova PF, Thrasher JB, Li B. Lithium suppresses cell proliferation by interrupting E2F-DNA interaction and subsequently reducing S-phase gene expression in prostate cancer. Prostate 2007;67:976-88.
12. Cohen P, Goedert M. GSK3 inhibitors: Development and therapeutic potential. Nat Rev Drug Discov 2004;3:479-87.
13. Zhu Q, Yang J, Han S, Liu J, Holzbeierlein J, Thrasher JB, et al. Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate 2011;71:835-45.
14. Liao X, Thrasher JB, Holzbeierlein J, Stanley S, Li B. Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 2004;145:2941-9.
15. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
16. Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, et al. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 2001;28:62-6.
17. Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl Recept Signal 2008;6:e001.
18. Roy S, Kaur M, Agarwal C, Tecklenburg M, Sclafani RA, Agarwal R. p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther 2007;6:2696-707.
19. Dorr RT, Von-Hoff DD. Drug monographs. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, Conneticut: Appleton and Lange; 1994. p. 395-416.
20. Van Brussel JP, Van Steenbrugge GJ, Romijn JC, Schröder FH, Mickisch GH. Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer 1999;35:664-71.
21. Li R, Erdamar S, Dai H, Sayeeduddin M, Frolov A, Wheeler TM, et al. Cytoplasmic accumulation of glycogen synthase kinase-3beta is associated with aggressive clinicopathological features in human prostate cancer. Anticancer Res 2009;29:2077-81.
22. Rinnab L, Schütz SV, Diesch J, Schmid E, Küfer R, Hautmann RE, et al. Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: Are GSK inhibitors therapeutically useful? Neoplasia 2008;10:624-34.
23. Brown BW, Thompson JR. A rationale for synchrony strategies in chemotherapy. In: Ludwig C, editor. Epidemiology. Philadelphia: SIAM Publication; 1975. p. 31-48.
24. Takahashi-Yanaga F, Sasaguri T. GSK-3beta regulates cyclin D1 expression: A new target for chemotherapy. Cell Signal 2008;20:581-9.
25. Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, et al. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 1999;59:2551-6.